International orthopaedics · 2026
Revision total hip arthroplasty with limb shortening for symptomatic leg length discrepancy: survivorship and clinical outcomes at mean seven-year follow-up.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chaudhry Faran, Bridger Adam, Daud Anser, Greenberg Arieh, Safir Oleg, Gross Allan, Kuzyk Paul
Аннотация
PURPOSE: This study evaluates the survivorship and clinical outcomes of revision total hip arthroplasty (THA) to treat symptomatic leg length discrepancy (LLD) via limb shortening.
METHODS: A total of ten patients were included who underwent revision THA to treat LLD via limb shortening at a single arthroplasty center from January 1, 2000, to December 31, 2022, representing 0.4% (ten of 2763) of all revision THA during this period. Among these cases, six of ten (60.0%) were men, mean age at index surgery was 62 years (range, 39 to 81), and mean follow-up was 7.63 years (range, 3.51 to 15.73). Kaplan-Meier survivorship analysis was conducted with failure defined as revision surgery for any reason.
RESULTS: Kaplan-Meier survivorship for failure due to any cause was 100.0% at five years, with nine hips at risk and 80.0% at ten and 15 years with one hip at risk. One patient failed due to dislocation. The mean LLD significantly improved from a pre-operative value of 24.5 mm (SD 7.25) to a post-operative value of 1.25 mm (SD 3.17) (P < 0.001). There was a significant increase in Harris hip scores from 50.44 (SD 11.11) pre-operatively to 75.4 (SD 19.35) at one year (P = 0.0172) and 84.6 (SD 12.44) at three years post-operatively (P = 0.011).
CONCLUSION: Revision total hip arthroplasty to treat LLD via limb shortening provides favourable 5- to 10-year survivorship and clinical outcomes.
METHODS: A total of ten patients were included who underwent revision THA to treat LLD via limb shortening at a single arthroplasty center from January 1, 2000, to December 31, 2022, representing 0.4% (ten of 2763) of all revision THA during this period. Among these cases, six of ten (60.0%) were men, mean age at index surgery was 62 years (range, 39 to 81), and mean follow-up was 7.63 years (range, 3.51 to 15.73). Kaplan-Meier survivorship analysis was conducted with failure defined as revision surgery for any reason.
RESULTS: Kaplan-Meier survivorship for failure due to any cause was 100.0% at five years, with nine hips at risk and 80.0% at ten and 15 years with one hip at risk. One patient failed due to dislocation. The mean LLD significantly improved from a pre-operative value of 24.5 mm (SD 7.25) to a post-operative value of 1.25 mm (SD 3.17) (P < 0.001). There was a significant increase in Harris hip scores from 50.44 (SD 11.11) pre-operatively to 75.4 (SD 19.35) at one year (P = 0.0172) and 84.6 (SD 12.44) at three years post-operatively (P = 0.011).
CONCLUSION: Revision total hip arthroplasty to treat LLD via limb shortening provides favourable 5- to 10-year survivorship and clinical outcomes.